Company
Headquarters: Boston, MA, United States
Employees: 41
CEO: Dr. Rahul D. Ballal Ph.D.
$413.7 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and à-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2Ârelated factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Last Financial Reports Date | Dec. 31, 2022 |
| Revenue TTM | $0 |
| EBITDA | $0 |
| Gross Profit TTM | $0 |
| Profit Margin | % |
| Operating Margin | % |
| Quarterly Revenue Growth | % |
IMARA Inc. has the following listings and related stock indices.
Stock: NASDAQ: IMRA wb_incandescent